|
ALLO Allogene Therapeutics Inc 1737287 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-42,607,000.00 |
| Balance Sheet |
|
Current Assets
|
$273,293,000.00 |
|
Assets
|
$395,958,000.00 |
|
Current Liabilities
|
$28,330,000.00 |
|
Liabilities
|
$117,083,000.00 |
|
Equity
|
$278,875,000.00 |
|
Shares Out
|
244816413.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-12,913,000.00 |
|
Investing Cash Flow
|
$-29,588,000.00 |
| Market Analysis |
Market Cap
|
$482,288,333.61 |
|
Price
|
$1.81 |
|
BVPS
|
1.14 |
|
PB
|
1.73 |
|
EPS
|
-0.18 |
|
FCF
|
$-12,922,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:27 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:23 |
|
| Apr |
May |
Jun |
| 2026-03-12 |
-0.17 |
|
|
2026-05-13 |
-0.18 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-13 |
-0.23 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-06 |
-0.19 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view ALLO documents filed with the SEC.
ALLO Filings
Clear
